NO20020042D0 - Kinazolinderivater - Google Patents
KinazolinderivaterInfo
- Publication number
- NO20020042D0 NO20020042D0 NO20020042A NO20020042A NO20020042D0 NO 20020042 D0 NO20020042 D0 NO 20020042D0 NO 20020042 A NO20020042 A NO 20020042A NO 20020042 A NO20020042 A NO 20020042A NO 20020042 D0 NO20020042 D0 NO 20020042D0
- Authority
- NO
- Norway
- Prior art keywords
- alkyl
- aryl
- heterocyclyl
- formula
- group
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/94—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Quinoline Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Seal Device For Vehicle (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP99401692 | 1999-07-07 | ||
| EP00401221 | 2000-05-04 | ||
| PCT/GB2000/002566 WO2001004102A1 (en) | 1999-07-07 | 2000-07-04 | Quinazoline derivatives |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO20020042D0 true NO20020042D0 (no) | 2002-01-04 |
| NO20020042L NO20020042L (no) | 2002-03-04 |
Family
ID=26073473
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20020042A NO20020042L (no) | 1999-07-07 | 2002-01-04 | Kinazoline derivater |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US6806274B1 (no) |
| EP (1) | EP1218353B1 (no) |
| JP (1) | JP2003504360A (no) |
| KR (1) | KR20020029419A (no) |
| CN (1) | CN1360582A (no) |
| AT (1) | ATE375984T1 (no) |
| AU (1) | AU6578900A (no) |
| BR (1) | BR0012157A (no) |
| CA (1) | CA2378291A1 (no) |
| DE (1) | DE60036812T2 (no) |
| ES (1) | ES2292461T3 (no) |
| IL (1) | IL147280A0 (no) |
| MX (1) | MXPA01012887A (no) |
| NO (1) | NO20020042L (no) |
| WO (1) | WO2001004102A1 (no) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2001235804A1 (en) * | 2000-03-06 | 2001-09-17 | Astrazeneca Ab | Therapy |
| DE60136459D1 (de) * | 2000-06-24 | 2008-12-18 | Astrazeneca Ab | Guanidin-derivate von chinazoin zur behandlung von autoimmunkrankheiten |
| US6503914B1 (en) | 2000-10-23 | 2003-01-07 | Board Of Regents, The University Of Texas System | Thienopyrimidine-based inhibitors of the Src family |
| WO2002036587A2 (en) | 2000-11-01 | 2002-05-10 | Cor Therapeutics, Inc. | Process for the production of 4-quinazolinylpiperazin-1-carboxylic acid phenylamides |
| GB0128108D0 (en) | 2001-11-23 | 2002-01-16 | Astrazeneca Ab | Therapeutic use |
| CN101607958A (zh) | 2002-02-01 | 2009-12-23 | 阿斯特拉曾尼卡有限公司 | 喹唑啉化合物 |
| US6924285B2 (en) | 2002-03-30 | 2005-08-02 | Boehringer Ingelheim Pharma Gmbh & Co. | Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them |
| GB0208224D0 (en) * | 2002-04-10 | 2002-05-22 | Celltech R&D Ltd | Chemical compounds |
| GB0221245D0 (en) * | 2002-09-13 | 2002-10-23 | Astrazeneca Ab | Chemical process |
| GB0317665D0 (en) | 2003-07-29 | 2003-09-03 | Astrazeneca Ab | Qinazoline derivatives |
| EP1713781B1 (en) | 2004-02-03 | 2008-11-05 | AstraZeneca AB | Quinazoline derivatives |
| AR056200A1 (es) * | 2005-09-27 | 2007-09-26 | Wyeth Corp | Tieno [2,3-b]piridin-5-carbonitrilos como inhibidores de proteina quinasa |
| EP1921070A1 (de) | 2006-11-10 | 2008-05-14 | Boehringer Ingelheim Pharma GmbH & Co. KG | Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstelllung |
| MX2009007610A (es) | 2007-02-06 | 2009-07-24 | Boehringer Ingelheim Int | Heterociclicos biciclicos, medicamentos que contienen estos compuestos, su utilizacion y procedimientos para su preparacion. |
| US7951832B2 (en) | 2007-10-31 | 2011-05-31 | Burnham Institute For Medical Research | Pyrazole derivatives as kinase inhibitors |
| WO2009098061A1 (de) | 2008-02-07 | 2009-08-13 | Boehringer Ingelheim International Gmbh | Spirocyclische heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung |
| NZ589883A (en) | 2008-05-13 | 2012-06-29 | Astrazeneca Ab | Fumarate salt of 4- (3-chloro-2-fluoroanilino) -7-methoxy-6- { [1- (n-methylcarbamoylmethyl) piperidin- 4-yl] oxy} quinazoline |
| JP5539351B2 (ja) | 2008-08-08 | 2014-07-02 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | シクロヘキシルオキシ置換ヘテロ環、これらの化合物を含有する医薬、およびそれらを生成するための方法 |
| CN102068434B (zh) * | 2011-01-25 | 2012-08-22 | 林治华 | 4-(环己基)-胺基喹唑啉类化合物的应用 |
| CU24406B1 (es) * | 2014-04-04 | 2019-05-03 | Pfizer | 1-{[(2s,3s,4s)-3-etil-4-fluoro-5-oxopirrolidin-2-il]metoxi}-7 -metoxiisoquinolin-6-carboxamida |
| JP6989505B2 (ja) | 2015-08-28 | 2022-01-05 | コーネル ユニヴァーシティー | Ｍａｌｔ１阻害剤およびその使用 |
| CN109689652B (zh) * | 2016-08-23 | 2022-04-26 | 北京诺诚健华医药科技有限公司 | 稠杂环类衍生物、其制备方法及其在医学上的应用 |
| JP7097880B2 (ja) * | 2016-11-01 | 2022-07-08 | コーネル ユニバーシティー | Ｍａｌｔ１分解のための化合物 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4659736A (en) * | 1984-01-21 | 1987-04-21 | Bayer Aktiengesellschaft | Benzoyl urea compounds as agents for repelling snails and slugs |
| JPH0720943B2 (ja) * | 1988-08-19 | 1995-03-08 | 宇部興産株式会社 | アミノピリミジン誘導体、その製法及び殺虫・殺菌剤 |
| JPH11503110A (ja) * | 1995-02-17 | 1999-03-23 | スミスクライン・ビーチャム・コーポレイション | Ｉｌ−８受容体拮抗剤 |
| US5773459A (en) | 1995-06-07 | 1998-06-30 | Sugen, Inc. | Urea- and thiourea-type compounds |
| GB9514265D0 (en) | 1995-07-13 | 1995-09-13 | Wellcome Found | Hetrocyclic compounds |
| CA2282439C (en) * | 1997-03-05 | 2010-05-04 | Sugen, Inc. | Formulations for hydrophobic pharmaceutical agents |
| AR012634A1 (es) * | 1997-05-02 | 2000-11-08 | Sugen Inc | Compuesto basado en quinazolina, composicion famaceutica que lo comprende, metodo para sintetizarlo, su uso, metodos de modulacion de la funcion deserina/treonina proteinaquinasa con dicho compuesto y metodo in vitro para identificar compuestos que modulan dicha funcion |
| CA2289731A1 (en) | 1997-05-09 | 1998-11-12 | The United States Of America, Represented By The Secretary, Department O F Health And Human Services | Methods and compositions for reducing ischemic injury of the heart by administering adenosine receptor agonists and antagonists |
| WO1998052558A1 (en) | 1997-05-23 | 1998-11-26 | Bayer Corporation | INHIBITION OF p38 KINASE ACTIVITY BY ARYL UREAS |
| AR016817A1 (es) | 1997-08-14 | 2001-08-01 | Smithkline Beecham Plc | Derivados de fenilurea o feniltiourea, procedimiento para su preparacion, coleccion de compuestos, compuestos intermediarios, composicion farmaceutica,metodo de tratamiento y uso de dichos compuestos para la manufactura de un medicamento |
| US6492393B1 (en) * | 1999-11-16 | 2002-12-10 | Boehringer Ingelheim Pharmaceuticals, Inc. | Compounds useful as anti-inflammatory agents |
| DE60136459D1 (de) | 2000-06-24 | 2008-12-18 | Astrazeneca Ab | Guanidin-derivate von chinazoin zur behandlung von autoimmunkrankheiten |
| US7074805B2 (en) * | 2002-02-20 | 2006-07-11 | Abbott Laboratories | Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor |
-
2000
- 2000-07-04 JP JP2001509712A patent/JP2003504360A/ja not_active Withdrawn
- 2000-07-04 US US10/019,945 patent/US6806274B1/en not_active Expired - Fee Related
- 2000-07-04 CN CN00810040A patent/CN1360582A/zh active Pending
- 2000-07-04 AT AT00953271T patent/ATE375984T1/de not_active IP Right Cessation
- 2000-07-04 AU AU65789/00A patent/AU6578900A/en not_active Abandoned
- 2000-07-04 EP EP00953271A patent/EP1218353B1/en not_active Expired - Lifetime
- 2000-07-04 KR KR1020027000188A patent/KR20020029419A/ko not_active Application Discontinuation
- 2000-07-04 BR BR0012157-6A patent/BR0012157A/pt not_active Application Discontinuation
- 2000-07-04 IL IL14728000A patent/IL147280A0/xx unknown
- 2000-07-04 MX MXPA01012887A patent/MXPA01012887A/es unknown
- 2000-07-04 CA CA002378291A patent/CA2378291A1/en not_active Abandoned
- 2000-07-04 ES ES00953271T patent/ES2292461T3/es not_active Expired - Lifetime
- 2000-07-04 DE DE60036812T patent/DE60036812T2/de not_active Expired - Fee Related
- 2000-07-04 WO PCT/GB2000/002566 patent/WO2001004102A1/en active Search and Examination
-
2002
- 2002-01-04 NO NO20020042A patent/NO20020042L/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DE60036812D1 (de) | 2007-11-29 |
| DE60036812T2 (de) | 2008-07-17 |
| ES2292461T3 (es) | 2008-03-16 |
| WO2001004102A1 (en) | 2001-01-18 |
| JP2003504360A (ja) | 2003-02-04 |
| MXPA01012887A (es) | 2002-07-30 |
| EP1218353A1 (en) | 2002-07-03 |
| EP1218353B1 (en) | 2007-10-17 |
| CA2378291A1 (en) | 2001-01-18 |
| BR0012157A (pt) | 2002-04-02 |
| ATE375984T1 (de) | 2007-11-15 |
| KR20020029419A (ko) | 2002-04-18 |
| NO20020042L (no) | 2002-03-04 |
| CN1360582A (zh) | 2002-07-24 |
| US6806274B1 (en) | 2004-10-19 |
| AU6578900A (en) | 2001-01-30 |
| IL147280A0 (en) | 2002-08-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20020042D0 (no) | Kinazolinderivater | |
| AU2001235804A1 (en) | Therapy | |
| NO20021728L (no) | Pyrimidin derivater | |
| ATE303357T1 (de) | Amid-derivate | |
| PL346854A1 (en) | Benzamide derivatives and their use as cytokine inhibitors | |
| GB0128108D0 (en) | Therapeutic use | |
| MY140729A (en) | Amide derivatives | |
| ATE233754T1 (de) | Diphenyl-piperidin derivate | |
| TW200728291A (en) | Amide derivatives | |
| ATE413394T1 (de) | Guanidin-derivate von chinazoin zur behandlung von autoimmunkrankheiten | |
| DE60035429D1 (de) | Verwendung von sulfodehydroabietinsäure zur behandlung entzündlicher darmerkrankungen | |
| GB0128109D0 (en) | Therapeutic use | |
| HUP0203161A2 (hu) | Benzamidinszármazékok, eljárás az előállításukra, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk | |
| NO973242L (no) | Anvendelse av 3,4-difenylkromaner til fremstilling av et farmasöytisk preparat for behandling eller profylakse av idiopatisk eller fysiologisk gynekomasti | |
| DE60022047D1 (de) | Antivirale therapie | |
| TH22511A (th) | Use of quinoxalines in combination with protease inhibitors as medicaments for treation, aids and/or hiv infections |